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are present on the basal surfaces of GEC in vivo. However, inDecay-accelerating factor expression in the rat kidney is re-
proteinuric conditions, DAF appears to be protective to GEC.stricted to the apical surface of podocytes.
Background. Decay-accelerating factor (DAF) has inhibi-
tory activity toward complement C3 and C5 convertases. DAF
is present in human glomeruli and on cultured human glomeru-
Complement activation can proceed via either the al-lar visceral epithelial cells (GEC). We studied the distribution
ternative, classical or mannose-binding lectin pathwaysand function of rat DAF.
Methods. Function-neutralizing antibodies (Abs) were raised [1, 2]. Activation through each of these pathways leads
against DAF. The distribution of DAF in vivo was determined to cleavage of C3 with generation of the proinflammatory
by immunoelectron microscopy. Functional studies were per-
and regulatory fragments, C3a and C3b. C3b attaches co-formed in cultured GEC and following IV injection of anti-
valently to immune complexes, which is followed by C5DAF Abs into rats.
Results. DAF was present exclusively on the apical surfaces binding and its cleavage to C5a and C5b. The former is
of GEC, and was not present on the basal surfaces of GEC, a potent inflammatory molecule that can recruit and ac-
nor other glomerular or kidney cells. DAF was functionally ac- tivate neutrophils and monocytes, while the generationtive on cultured GEC, and served to limit complement activa-
of C5b begins the non-enzymatic assembly of the C5b-9tion in concert with CD59, an inhibitor of C5b-9 formation.
membrane attack complex that can result in cellularUpon injection into normal rats, anti-DAF F(ab)2 Abs bound to
GEC in vivo, yet there was no evidence for complement activa- death or activation following membrane insertion [3].
tion and animals did not develop abnormal albuminuria. Anti- To prevent injury of self-tissue, complement is regu-
megalin complement-activating IgG Abs were “planted” on
lated by both plasma and cell membrane-associated pro-GEC, which activated complement as evidenced by the pres-
teins [4]. A focal point of regulation is at the level ofence of C3d on GEC. Attempts to inhibit DAF function with
anti-DAF Abs did not affect the quantity of complement acti- the C3/C5 convertases of both pathways. This occurs in
vation by these anti-megalin Abs, nor did it lead to develop- humans via the action of the plasma proteins, factor H
ment of abnormal albuminuria. In contrast, in the puromycin and C4-binding protein, and the cell membrane proteins,aminonucleoside model of GEC injury and proteinuria, anti-
complement receptor 1 (CR1), decay-accelerating factorDAF Abs slowed the recovery from renal failure that occurs
in this model. (DAF), and membrane cofactor protein, all members of
Conclusion. In cultured rat GEC, DAF is an effective com- the regulators of complement activation gene family [5].
plement regulator. In vivo, DAF is present on GEC apical sur- These proteins inhibit C3/C5 convertases by acceleratingfaces. Yet, it appears that DAF is not essential to prevent
their intrinsic decay and/or by acting as a factor I cofactorcomplement activation from occurring under normal circum-
for the cleavage and inactivation of C3b and C4b. Thestances and in those cases in which complement-activating Abs
related rodent protein, Crry (CR1-related gene/protein y),
has combined decay-accelerating and factor I cofactor
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activity for C3b and C4b [6, 7].nephritis, puromycin aminonucleoside nephrosis, proteinuria, renal
injury. The complement system is considered to be relevant
to a number of diseases affecting the glomerulus [8]. In
Received for publication October 1, 2001
most cases of immunologically-mediated glomerular dis-and in revised form June 10, 2002
Accepted for publication July 8, 2002 eases, complement components are found in diseased
glomeruli. Furthermore, in some disease states, such as 2002 by the International Society of Nephrology
2010
Bao et al: Rat glomerular epithelial cell DAF 2011
lupus nephritis, postinfectious glomerulonephritis (GN), chromatography on a column of recombinant DAF
bound to CNBr-Sepharose [31] was utilized. Monoclonaland membranoproliferative GN, systemic complement
consumption is evident. A considerable amount of exper- mouse anti-rat DAF Ab clone RDIII-7 was generated
as previously described [29].imental evidence also has been accumulated from animal
models that has shed additional light on the role for com- Mouse hybridoma clones K57/27 and K35/9 producing
anti-rat megalin (gp330) monoclonal Abs were kindlyplement activation in human glomerular diseases [9].
One of the most thoroughly studied glomerular dis- provided by Dr. Donna Mendrick (Gene Logic, Inc.,
Gaithersburg, MD, USA) [32]. These clones were cul-ease models and for which data have been accumulated
implicating a role for the complement system is the Hey- tured and IgG isolated from supernatants by protein G
affinity chromatography. The IgG was concentrated andmann nephritis (HN) model of membranous nephropa-
thy [10]. In the passive HN model, injected anti-Fx1A dialyzed into 150 mmol/L NaCl. To confirm the reactivity
of the mAbs against megalin, indirect immunofluores-antibodies (Abs) bind to megalin and other visceral glo-
merular epithelial cell (GEC) antigens [11–13]. When a cence (IF) staining was performed on normal rat kidney
documenting strongly positive proximal tubular brushthreshold amount of Abs has accumulated, complement
activation can proceed, C5b-9 is generated, and GEC border staining [32].
Polyclonal sheep Abs to recombinant rat CD59 wereinjury occurs [14–17]. As the GEC appears to be key to
the integrity of the glomerular permselectivity barrier, raised as previously detailed [31]. Monoclonal anti-rat
CD59 clone 6D1 also has been described [33]. Both Absan acquired or inherited abnormality of the GEC is suf-
ficient to lead to the development of abnormal protein- neutralize the function of CD59 in vitro and in vivo [27, 31].
Rabbit anti-rat erythrocyte Abs were raised and absorbeduria [18], as occurs in passive HN. Consistent with this
theme is that the relatively specific toxin for GEC, puro- against recombinant rat CD59 [34]. Rabbit anti-rat GEC
Abs were produced as described previously [13].mycin aminonucleoside (PAN) leads to marked protein-
uria in the PAN nephrosis model [19, 20]. F(ab)2 fragments of sheep anti-DAF, anti-CD59 and
pre-immune IgG were obtained by pepsin digestion fol-There is a balance between complement activation and
its regulation [21]. By histological techniques, human lowed by size exclusion chromatography [28]. Sodium do-
decyl sulfate-polyacrylamide gel electrophoresis (SDS-glomeruli contain all of the regulators of complement ac-
tivation members, and these may be up-regulated under PAGE) was used to verify the purity of all IgG and
F(ab)2 Abs.disease states in which complement is activated [22–24].
In vitro, cultured human GEC bear functionally active
Functional studiesDAF [25].
The situation in rat glomeruli appears comparable to Rat erythrocytes were sensitized by incubation (15
min, 37C) with a 1/100 dilution in phosphate-bufferedthat in humans. Crry is present in glomerular cells in vitro
and in vivo [26, 27]. In the case of GEC, Crry limits com- saline (PBS) of anti-erythrocyte Abs. Blocking anti-rat
CD59 mAb 6D1 (10 g/mL) and/or affinity-purifiedplement activation through both classical and alternative
pathways in vitro [6, 7], and is responsible for limiting sheep anti-rat DAF F(ab)2 (10 g/mL) were included in
the sensitization step. Sensitized erythrocytes were washedcomplement activation in the active HN model in vivo
[28]. Originally, investigators in the field considered Crry into 0.14 mol/L NaCl, 0.01 mol/L Na barbital, pH 7.4
(VBS) and incubated (30 min, 37C) with serial dilutionsto replace both DAF and membrane cofactor protein in
glomeruli. However, with the identification of rat DAF, of normal rat serum (NRS) diluted in VBS. Hemoglobin
released into the supernatants was expressed as a per-it is clear that this assumption was incorrect [29, 30]. In
this study, we characterized rat DAF that is exclusively centage of that maximally released by H2O.
Rat GEC were cultured and studied for complementpresent on GEC in the kidney.
regulation as previously described [27]. In this technique,
the release of the previously cell-incorporated fluores-
METHODS
cent probe, biscarboxyethyl carboxyfluorescein (BCECF;
Antibodies Molecular Probes, Eugene, OR, USA) was used as a
marker of complement-mediated cytotoxicity. Cells wereRecombinant rat DAF was produced as described pre-
viously [30]. A single sheep was immunized with DAF loaded with the acetoxymethyl ester of BCECF and sub-
sequently exposed to rabbit anti-GEC IgG at 1 mg/mLin complete Freund’s adjuvant for the primary immuni-
zation and incomplete Freund’s adjuvant for booster im- in VBS. In this step, some cells were also exposed to
sheep anti-DAF and/or anti-CD59 F(ab)2 at 0.3 mg/mLmunizations (Charles River Pharmservices, Southbridge,
MA, USA). IgG was purified from pre-immune and im- in VBS. Subsequently, cells were incubated in 40% NRS
for 40 minutes at 37C, and BCECF released into themune sera by protein G affinity chromatography (Amer-
sham Pharmacia Biotech, Piscataway, NJ, USA). In some supernatants was measured spectrofluorimetrically and
expressed as a percentage of that maximally released bystudies, affinity purified anti-DAF produced by affinity
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melittin (50 g/mL; Sigma Aldrich, St. Louis, MO, USA). [37]. On the eighth day of disease, all animals underwent
survival renal biopsies to determine intrinsic DAF distri-Control cells were treated identically, yet not exposed
to Ab nor to serum, and were used to determine the bution, and then animals were given either 20 mg sheep
anti-DAF (N  4) or pre-immune sheep IgG (N  5).spontaneous leakage of BCECF [35].
Survival renal biopsies were performed 9 and 10 days
Animal experiments after PAN injection (N  2 to 3 in each group) to de-
termine intrinsic DAF and sheep anti-DAF Ab distribu-All work with animals was approved by the University
of Chicago Animal Care and Use Committee and were tion. Serum and urine samples were collected at selected
times from days 0 to 11. On the eleventh day after PANperformed in accord with the NIH Guide for the Care
and Use of Laboratory Animals. Male Sprague-Dawley injection, all rats were sacrificed and renal tissue was
harvested.rats weighing 225 to 250 grams were purchased from Har-
lan Sprague Dawley, Inc. (Indianapolis, IN, USA). Inha-
Measurements from blood and urinelational isoflurane was used to anesthetize rats during
all procedures. Blood was first drawn into a heparinized micro-hema-
tocrit capillary tube for hematocrit determination, fol-In the first group of studies, anti-rat DAF F(ab)2 Abs
were injected intravenously into normal rats. To examine lowed by collection for serum isolation. Blood urea nitro-
gen (BUN) and urinary creatinine concentrations werethe localization of injected anti-DAF, whether intrinsic
DAF might be modulated, and if neutralization of DAF measured with a Beckman Autoanalyzer (Beckman In-
struments, Fullerton, CA, USA). Urinary albumin wasfunction affected the glomerular permselectivity barrier
to protein passage, groups of two rats each were injected measured by a previously described enzyme-linked im-
munosorbent assay (ELISA) technique [38]. Urinary ex-IV with 10, 20 and 40 mg anti-rat DAF F(ab)2. Animals
were studied within 24 hours of Ab injection, with the cretion of albumin was normalized to urinary creatinine
and expresses as g albumin/mg creatinine. Urinary pro-rationale that injected F(ab)2 Abs would have ready
access to the GEC in vivo [36]. Within four hours of Ab tein was measured with sulfosalicyclic acid [28] and data
are presented as mg protein per 24 hours.injection, animals were housed for 24 hours in metabolic
cages for urine collection, and then sacrificed for blood
Tissue processingand tissue harvest.
In the second group of studies, the role of DAF in Portions of renal tissue were formalin fixed and em-
bedded in HistoPrep (Fisher Scientific, Pittsburgh, PA,passive HN was determined. For these studies, 15 mg
each of anti-megalin monoclonal Abs K57/27 and K35/9 USA) and snap frozen in isopentane on dry ice. For light
microscopy, 4 m sections were stained with periodicwere injected into rats. As is known from past studies by
Salant et al [17] and verified in our prior studies with acid Schiff and provided as coded slides to a renal pa-
thologist (MH). In the PAN studies, the percentage ofthese anti-megalin Abs [31], there is progressive glomer-
ular accumulation of anti-megalin Abs over time. By five total glomerular area occupied by sclerosis and/or hyali-
nosis was estimated. In addition, the grading of tubulardays following injection, significant subepithelial im-
mune deposits and immunoreactive C3d are present, the changes was done using a modification of the protocol
of Nomura et al [39]. The extent of cast formation, dila-latter evidence for complement activation, yet, there is
not increased proteinuria, unlike passive HN induced tion and degenerative changes in tubules in the cortex
and outer stripe of the outer medulla was quantified onby anti-Fx1A Abs [31]. The role for DAF in limiting
complement activation in the setting in which anti-mega- a 0 to 3 scale, in which 0 was no involvement; 0.5 
10%; 1  10 to 20%; 2  30 to 70%; and; 3  70%lin Abs were present on GEC was studied by injecting
four animals with 20 mg anti-DAF F(ab)2. Control ani- of tubules involved. A composite tubular injury score
was arrived at by summing the three individual scoresmals (N  4) were treated identically except they re-
ceived pre-immune F(ab)2 instead of anti-DAF. Be- from each animal.
For immunofluorescence (IF) microscopy, 4 m cryo-cause in vitro studies in erythrocytes and GEC suggested
that even with DAF neutralization, complement activa- stat sections were directly stained for sheep F(ab)2 and
rat C3 using fluorescein isothiocyanate (FITC)-conju-tion was limited by functional CD59 (see below), a third
group of animals with GEC-bound anti-megalin Abs re- gated Abs (Cappel Laboratories, Durham, NC, USA).
Since the latter detects only C3c, staining for C3d wasceived 20 mg anti-DAF and anti-CD59 F(ab)2. In each
of these three groups, following injection of F(ab)2 Abs, done using a specific anti-human C3d Ab (Dako, Car-
pinteria, CA, USA), which is cross-reactive with rat C3durine was collected for 24 hours and animals were then
sacrificed. [40]. An indirect IF procedure was used to detect rat
DAF in which sheep anti-rat DAF was followed byIn a third group of studies, the role of DAF was studied
in the PAN nephrosis model that was induced by a single FITC-conjugated anti-sheep IgG. For dual detection of
rat DAF and sheep anti-DAF F(ab)2 in tissue sections,IP injection of 15 mg PAN (Sigma) per 100 g body weight
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FITC-conjugated anti-sheep F(ab)2, monoclonal anti- RESULTS
rat DAF, and rhodamine-conjugated sheep anti-mouse Localization of DAF in normal rat kidneys
IgG (Cappel) were incubated in succession. A semiquan- Using an indirect IF technique, DAF was very strongly
titative scoring system was used in which each slide was expressed in rat glomeruli (Fig. 1). Although the staining
scored from 0 (negative) to 4 (strongest) using a schema pattern was consistent with GEC localization of DAF
previously published [38]. In all cases, the observer was (arrows), the higher resolution technique of immuno-
blinded as to the origin of the slides. electron microscopy was used to definitively localize rat
DAF in kidney. Indirect immunoperoxidase techniques
Immunoelectron microscopy
localized DAF specifically to the apical surfaces of podo-
A kidney from an adult Sprague-Dawley rat was col- cytes and their foot processes. As shown in Figure 2, elec-
lected and fixed with 1% paraformaldehyde-0.05% glu- tron dense peroxidase reaction product was found ex-
taraldehyde in 0.1 mol/L phosphate buffer, pH 7.3 for clusively and diffusely on apical membrane domains of
11⁄2 hours on ice. Fixative was washed out using 0.1 mol/L podocytes. In contrast, no reaction product was detected
phosphate buffer, pH 7.3 and tissue was equilibrated in on endothelial cell surfaces, within the GBM, or on basal
30% sucrose in buffer. Samples were frozen in OCT us- cell surfaces of podocyte foot processes adherent to the
ing isopentane chilled in a bath of acetone and dry ice. GBM (Fig. 2). Similarly, glomerular mesangial cells, tu-
Frozen sections, 30 m thick, were picked up on Nunc bular epithelial cells, and all tubulointerstitial cells in the
Thermanox coverslips (Nalge Nunc International, Ro- kidney were completely negative, as were control tissues
chester, NY, USA) that were air-dried for two hours incubated with irrelevant sheep IgG (not shown).
and used the same day or stored at 4C. Sections were
Functional role of DAF on rat erythrocytes andblocked with 0.5 mol/L ammonium chloride in PBS for
cultured GEC30 minutes and then with 5% normal rabbit serum in
The role of DAF to limit complement activation on ratPBS for 30 minutes. Sections were incubated with 15
erythrocytes was studied. In these experiments, classicalg/mL affinity purified sheep anti-DAF F(ab)2 or ir-
pathway complement activation was induced by sensitiz-relevant sheep IgG as a control, for one hour at room
ing erythrocytes with a polyclonal Ab followed by expo-temperature in a humid chamber, washed with PBS, and
sure to NRS as a source of complement. As shown in Fig-incubated with rabbit anti-sheep F(ab)2-HRP (ICN Bio-
ure 3, rat erythrocytes were protected from activationmedicals, Inc., Irvine, CA, USA) diluted l:500 for one
of homologous complement. Inhibition of DAF functionhour. After washing with PBS, sections were re-fixed with
alone with neutralizing Abs led to a small, but significantKarnovsky’s fixative (using 0.1 mol/L phosphate buffer,
increase in hemolysis. Inhibition of CD59 caused a largerpH 7.3) for 15 minutes and then washed using 0.1 mol/L
increase in hemolysis, but when both DAF and CD59phosphate buffer, pH 7.3. Peroxidase histochemistry was
were neutralized, there was marked increase in hemoly-carried out using 0.05% DAB–0.01% H2O2 in 0.1 mol/L
sis, consistent with having impaired complement regula-phosphate buffer, pH 6.0 for one hour. Coverslips were
tion both at the level of C3/C5 convertases and at C5b-9washed with buffer and post-fixed with 2% OsO4 in 0.1 formation.mol/L phosphate buffer, pH 7.3 for 11⁄2 hours, dehydrated Given the prominent expression of DAF in rat GECthrough 100% ethanol, and infiltrated with graded mix-
in vivo, the complement regulatory activities of DAF
tures of ethanol/Polybed 812 into 100% Polybed 812
in cultured rat GEC were explored. In these studies,
(Polysciences, Warrington, PA, USA). Samples were po- both spontaneous alternative pathway activation and
lymerized in 35 mm dishes with fresh Polybed 812 over- Ab-mediated classical pathway activation were studied.
night at 60C, peeled from coverslips, and adhered to Given the absence of megalin on cultured rat GEC, a
the flat end of polymerized stubs. Ultrathin sections were polyclonal complement-activating Ab was used instead
stained with Reynold’s lead citrate for two minutes and [27]. As shown in Figure 4, GEC effectively regulated
viewed with a JEOL 100CX electron microscope (JEOL, complement activation through both pathways. In partic-
Tokyo, Japan). ular, GEC that were not Ab-sensitized but exposed to
serum as a complement source did not release BCECF
Statistics above that spontaneously released by cells exposed to
Statistical analyses were performed with Minitab Soft- buffer alone, indicating GEC can completely prevent
ware (College Park, MD, USA). Data are expressed as spontaneous activation of complement through the alter-
mean  SEM unless noted otherwise and statistical sig- native pathway. When the function of DAF alone was neu-
nificance was determined by one-way analysis of variance tralized there was a small enhancement in complement
(ANOVA) followed by Fisher’s pair-wise comparisons. activation. However, when the function of both DAF and
CD59 were neutralized on the surface of GEC, thereP values 0.05 were considered statistically significant.
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Fig. 1. Distribution of decay accelerating factor (DAF) in rat kidney by immunofluorescence (IF) microscopy. Normal rat kidney was stained
with affinity purified sheep anti-rat DAF F(ab)2 followed by FITC-conjugated anti-sheep IgG. The arrows depict apparent glomerular epithelial
cell (GEC) staining.
Fig. 5. Immunofluorescence staining for rat
DAF (A) and sheep F(ab)2 (B) 24 hours fol-
lowing injection of 40 mg sheep anti-rat DAF
F(ab)2. A dual labeling technique was utilized
in which glomerular bound sheep anti-DAF
F(ab)2 was detected with a specific FITC-con-
jugated Ab and intrinsic DAF was identified
by a monoclonal anti-DAF followed by a spe-
cific rhodamine-conjugated Ab. The arrow
depicts tubular resorption droplets of sheep
F(ab)2.
was markedly increased cytotoxicity occurring from both studies indicated that, while injected anti-DAF F(ab)2
classical and alternative pathway complement activation. could be identified in glomeruli as early as 10 minutes
after IV injection, significant Ab binding was present at
Functional role of DAF on GEC in vivo 24 hours post-injection, consistent with our past studies
and those by Salant et al, in which injected F(ab)2 AbsInitial studies sought to determine the fate of intra-
appear to readily cross the glomerular capillary wall ac-venously injected anti-DAF F(ab)2 Abs as well as intrin-
sic DAF to which the Abs were directed. Preliminary cessing the GEC [28, 36]; therefore, this time point was
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Fig. 2. Ultrastructural distribution of DAF by immunoelectron micros-
copy. Electron-dense peroxidase reaction product is seen exclusively
on the apical membrane surfaces (arrows) of GEC foot processes (Ep).
No labeling is detected on endothelial cells (En), within the glomerular
basement membrane (GBM), or on basal surfaces of podocytes. Abbre-
viations are: CL, capillary lumen; US, urinary space.
Fig. 3. Effects of neutralizing erythrocyte DAF and/or CD59 on classi-
cal pathway-mediated hemolysis. Antibody (Ab)-sensitized erythro-
cytes were exposed to function-neutralizing anti-DAF and/or anti-CD59
Abs, followed by varying dilutions of NRS as a complement source.chosen for subsequent experiments. Groups of two rats
The percent of maximal hemolysis was measured. Data are mean  SD
each were given 10, 20 or 40 mg anti-DAF F(ab)2, fol- (N  3 at each point). There was a statistically significant difference
between each condition at serum dilutions 1/20 and higher. Symbols are:lowing which urine was collected for 24 hours and ani-
() anti DAF & anti CD59; () anti-CD59; () anti-DAF; () none.mals were then sacrificed. There was a relationship be-
tween the dose of anti-DAF F(ab)2 administered and
the intensity of staining for sheep F(ab)2 in glomeruli
(Table 1). In contrast, although the intensity of staining
for intrinsic DAF was less than control rats, there did
not appear to be a relationship between immunoreactive
DAF remaining after Ab injection and the dose of the
Ab. Figure 5 shows a glomerulus from a rat injected with
the highest anti-DAF dose doubly stained for DAF and
sheep F(ab)2. Despite binding of function neutralizing
Abs to DAF, and apparent reduction in DAF amount,
there was no functional consequence apparent, either as
renal insufficiency, albuminuria, or C3 deposition by IF
microscopy (Table 1). Renal histology was similarly nor-
mal (not shown). Although altered DAF function has
the potential to result in hemolysis [41, 42], there was
no evidence for hemolysis in anti-DAF injected rats (Ta-
ble 1). These studies showed that alternative pathway
activation did not occur in vivo when the function of
DAF was inhibited, results comparable to the preceding
studies in vitro (as illustrated in Fig. 4). Fig. 4. Effects of neutralization of DAF and/or CD59 on GEC resis-
tance to complement activation. GEC were either not sensitized with AbThe question remained whether DAF protected against
() to evaluate alternative pathway activation or sensitized with anti-classical pathway activation. Therefore, studies were done
GEC ( ) to evaluate classical pathway activation. Cells were simultane-
in which GEC-reactive, complement-fixing Abs (anti- ously exposed to function-neutralizing anti-DAF and/or anti-CD59 F(ab)2
Abs, followed by 40% NRS as a complement source. The percent of maxi-megalin IgG2a monoclonal Abs) were present on the
mal release of BCECF was measured. Shown are data from one experi-GEC surface, following which the function of DAF was
ment, representative of four performed. Each point is mean SEM (N
neutralized with anti-DAF F(ab)2 Abs. Although mono- 3 at each point). P  0.05 vs. no Ab; *P  0.05 vs. all other groups.
clonal anti-megalin Abs alone result in a small amount
of detectable complement activation on GEC, there is
not abnormal proteinuria [31]. To confirm these findings
necessary to lead to complement activation in culturedin this study, a control group consisted of animals treated
GEC, a third group received anti-DAF and anti-CD59identically, except pre-immune sheep F(ab)2 was substi-
F(ab)2 together. Pathologic albuminuria was not foundtuted for anti-DAF F(ab)2. Given the preceding studies
in which combined neutralization of DAF and CD59 was in any group (Table 2). Despite inhibition of a potentially
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Table 1. Renal functional and morphologic data in rats injected with anti-DAF F(ab)2 Abs
Rat DAF Sheep F(ab)2 Rat C3aAnti-DAF dose BUN Hematocrit Albuminuria
mg mg/dL % lg/mg creatinine IF score
0 ND ND ND 3.3 0 0
10 21.6 48.0 16.5 1.3 0.5 0
20 17.5 49.5 15.0 1.3 0.8 0
40 23.8 48.0 12.0 1.5 2.0 0
Normal rats were injected with varying doses of anti-DAF F(ab)2, following which urine was collected and animals were then sacrificed for blood and renal tissue
collection. Data provided are the average of two animals studied in each group. ND is not done. Normal values are BUN 25 mg/dL, hematocrit 45–50%, and
albuminuria 25 g/mg creatinine.
a Staining was performed for both C3 and C3d
Table 2. Measures of complement activation in animals with plantedfunctional regulator of C3 activation, no difference in C3
anti-megalin antibodies (Abs) in which complement regulators
staining, either as C3c or C3d, was apparent (Table 2). were inhibited
A final group of studies addressed the question whe-
C3 C3d
F(ab)2 Abs Albuminuriather DAF was important to limit complement activation
injected on day 5 lg/mg creatinine IF scorethrough the alternative pathway. To create conditions in
Preimmune 9.51.8 0.60.1 1.00.2which alternative pathway complement activation could
Anti-DAF 12.32.8 0.60.1 1.00.2occur, the PAN nephrosis model was used, in which there
Anti-DAF and anti-CD59 14.33.1 0.50.1 0.90.1
is substantial protein passage across the glomerular capil-
Normal rats were injected with 15 mg each of K57/27 and K35/9 monoclonal
lary wall. Thus, all components of the alternative path- anti-rat megalin Abs. Five days later, they received 20 mg of the indicated F(ab)2
Abs. The following day, urine was collected for measurement of albuminuria,way would be accessible to GEC in this model. Within
and then animals were sacrificed and renal tissue stained for C3 and C3d.
six days of PAN injection, all animals had marked pro-
teinuria (Table 3) and a moderate degree of renal insuf-
ficiency (Fig. 6). At this time, there was a reduction in
immunoreactive DAF staining (IF score  1.7  0.1, brane cofactor protein, factor H and C4 binding protein,
compared to 3.0 in normal rats as shown in Fig. 1). all located on band q32 of human chromosome 1 [46].
While neutralization of DAF function by injection of Each protein is characterized by the presence of 60
anti-DAF Abs did not affect proteinuria (Table 3), it did amino acid short consensus repeats, which contain a frame-
slow the recovery from renal failure (Fig. 6). By day 11, work of four invariant cysteines forming two disulfide
all animals in the pre-immune IgG group had recovered bonds within each short consensus repeat [5, 46]. A char-
normal renal function (BUN 	30 mg/dL), while each acteristic in common among these proteins is their activ-
animal in the anti-DAF group had persistent renal insuf- ity to inhibit complement C3/C5 convertases, which is
ficiency (BUN 40 mg/dL). Intrinsic DAF and injected due to an affinity for C3b and/or C4b in these convertases.
anti-DAF colocalized with a somewhat granular appear- Soon after these human complement regulatory pro-
ance (Fig. 7). In all animals with PAN, there was marked teins were defined, homologous and analogous rodent
tubular complement deposition and only mild histologi- genes were described. In the mouse, a similar gene stretch
cal abnormalities (Fig. 8) that were not different between containing the regulators of complement activation fam-
the two groups (Table 3). There was only a mild extent ily members is also on chromosome 1 [47, 48]. There are
of glomerular C3 deposition prior to and after PAN in- some interesting differences between humans and mice,
jection (Fig. 8A). Even one day after anti-DAF injection, including the origin of CR1 and CR2 from the same gene
there was little C3 deposition (scores  0.5 and 1.0 in via alternative splicing, rather than from different genes
the two animals biopsied on day 9). Hence, intact DAF as in humans [49, 50]. Work by Weis et al identified a
function does appear to play a role in the recovery from
mouse gene product called Crry because of its similarity
acute renal failure occurring in the PAN nephrosis model.
to human CR1 [51]. In rats, work in the Okada lab iden-
tified a protein reactive with monoclonal antibody 5I2,
DISCUSSION which turned out to be rat Crry [52]. Because Crry has
the combined activities of DAF and membrane cofactorDecay activating factor was originally isolated by Nich-
protein, and neither of these two had been identified inolson-Weller et al from guinea pig and human erythro-
rodents, Crry was considered to be their functional ana-cytes [43, 44]. After its characterization, it became clear
log [6, 7]. Recently, however, the rodent homologs tothat there was a gene family of complement regulatory
DAF and membrane cofactor protein have been isolatedproteins to which DAF belonged, termed the regulators
and characterized [30, 48, 53–55].of complement activation gene cluster [45]. In humans,
the other members of this family are CR1, CR2, mem- In this study, we characterized rat DAF in kidney. By
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Table 3. Disease outcomes in animals with PAN nephrosis given anti-DAF
Proteinuria mg/day C3—glomeruli C3—tubules Histology—day 1l
Injection
Day 8 Day 5 Day 9 Day 8 Day 11 Day 8 Day 11 % sclerosis TI score
Preimmune 142.622.1 130.023.2 1.00.0 1.40.1 3.50.0 3.50.0 3.11.1 2.10.3
Anti-DAF 126.818.6 94.019.2 0.90.1 1.30.1 3.10.4 3.30.4 3.41.9 1.40.9
Normal rats were given a single PAN injection on day 0. On day 8, animals were injected with either preimmune or anti-DAF IgG. The indicated disease variables
were measured prior to (day 5 or 8) and after (day 9 or 11) antibody injection. A semiquantitative score of C3 staining in tubules and in glomeruli is provided.
Histological assessment of the percent of glomerulosclerosis and a composite tubular injury (TI) score were derived as described in the Methods section. There were
no statistical differences between preimmune and anti-DAF–injected groups in any of the measured variables.
apparatus, with lesser expression in cells of the glomeru-
lar capillary [23]. In disease states, there appears to be
up-regulated expression in glomeruli [59–61], perhaps be-
cause of signals transduced directly by the complement
activation [62].
While the study of DAF in human glomeruli is largely
limited to its expression patterns in normal and diseased
glomeruli, its role in rodents can be much more thor-
oughly evaluated. A widely used means of studying the
role of a protein is by inducing its deficiency through
targeted gene deletions. Both the Song and Medof labo-
ratories have deleted the gene for the GPI-linked form
of mouse DAF [42, 63]. These mice are phenotypically
normal, with no evidence for abnormal complement acti-
vation, consistent with the redundancy of complement
regulators. However, DAF-deficient mice had increasedFig. 6. Time course of renal function as measured by blood urea nitro-
gen (BUN) in puromycin aminonucleoside (PAN) nephrosis. Animals susceptibility to complement activation and disease man-
were given a single injection of PAN on day 0. On day 8 following
ifestations in two variants of the nephrotoxic serum ne-PAN injection, animals either received anti-DAF (N  4, ) or pre-
immune IgG (N  5, ). Data shown are mean  SEM. Where not phritis model [64, 65]. Mice have prominent glomerular
shown, the error bar falls within the point. *P 0.02 versus pre-immune. expression of DAF by IF microscopy [63], which is com-
parable to what we have shown here in rats. Furthermore,
DAF-deficient animals with nephrotoxic serum nephri-
tis developed GEC morphological abnormalities [65]IF microscopy, using either monoclonal or polyclonal
consistent with DAF having a functional role on GECAbs, DAF was strongly present in glomeruli in a pattern
in mice.consistent with GEC expression. That this was the case
Because of the apparent high expression of DAF onwas confirmed with the higher resolution technique of im-
rat GEC, and given our data on cultured rat GEC onmunoelectron microscopy, which showed that DAF was
which DAF limited complement activation, it seemedextensively and exclusively present on GEC. This pattern
likely that DAF present on GEC in vivo would be func-was unexpected, given the widespread distribution of DAF
tionally active. To examine this hypothesis, we utilizedin other rat organs, including in many vascular endothelia
polyclonal anti-DAF Abs that neutralized the function[29]. GEC in culture also contained functional DAF. As
of DAF in vitro. Upon IV injection into normal rats,expected from the known functions of human and rat
anti-DAF F(ab)2 Abs had ready access to GEC DAF,DAF [46, 56], rat GEC DAF protected against both al-
with both binding of Abs and apparent loss of DAFternative and classical pathway activation. Like human
possibly through antigenic modulation of the GPI-linkederythrocyte DAF, this protein on GEC is linked via a
DAF [66]. Despite this loss of immunoreactive DAFglyosylphosphatidyl insitol (GPI) anchor [25, 57].
protein and binding by inhibitory Abs, there was no evi-Our previous studies showed that DAF was present
dence that complement was activated, nor was the GECin cultured human GEC on which it was functionally ac-
altered, as evidenced by normal morphology and urinarytive, and that immunoreactive DAF was present in hu-
albumin excretion. This indicates that GEC complementman glomeruli [25]. At that time, there was some discrep-
regulation is unnecessary given its unique location be-ancy over the distribution of human DAF in kidney
yond the glomerular barrier to protein passage, and/or,[58, 59]. However, it is now clear DAF is expressed in
human glomeruli predominantly in the juxtaglomerular there are other complement regulators, such as Crry,
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Fig. 7. Immunofluorescence staining for rat DAF (A) and sheep IgG (B) following injection of sheep anti-rat DAF in PAN nephrosis. Shown is
IF from a single animal 9 days after PAN administration and 1 day after anti-DAF injection. The same dual labeling technique as described in
the legend to Fig. 5 was utilized to detect intrinsic DAF and glomerular bound sheep anti-DAF.
Fig. 8. Immunofluorescence staining for C3 (A) and histological features (B) in animals with PAN nephrosis given anti-DAF or pre-immune IgG.
There was intense staining for C3 primarily in the luminal aspects of proximal tubules in all animals. A glomerulus in the center shows a modest
extent of mesangial C3 staining that was typical for animals, with no difference apparent between those given anti-DAF and pre-immune IgG
(Table 3). (B) Examples of glomerular and tubular histological abnormalities. The glomerulus has segmental hyalinosis and GEC swelling, while
three tubular segments contain casts. Although several other histological features were seen, these occurred at the highest frequency.
which are in place to limit complement activation at the reflect productive complement activation leading to gen-
eration of C5b-9, we utilized anti-CD59 Abs in combina-level of C3 and C5 convertases [27].
Because of these negative results, combined with ob- tion with anti-DAF Abs. Not surprisingly, there was no
difference in C3 staining intensity, as inhibiting CD59servations in cultured cells that Ab-directed complement
activation was considerably more effective than sponta- would not be expected to affect C3 convertases. How-
ever, in the setting of anti-megalin Abs and neutraliza-neous (alternative pathway) complement activation, we
activated complement on GEC with anti-megalin Abs. tion of DAF and CD59 function, there was no increase in
albuminuria above normal. These findings are differentThus, in the setting of anti-megalin Abs, a small amount
of C3c and C3d was detected in glomeruli by IF micros- than in our earlier study in which Crry and CD59 were
inhibited, in which case, proteinuria was increased [31].copy, consistent with ongoing complement activation [40].
The possibility that DAF might limit complement activa- Taken together, these findings could indicate either that
Crry is the functional C3/C5 convertase regulator, ortion by these anti-megalin Abs was investigated by in-
jecting neutralizing Abs. Yet, in this setting, there was no that the GEC has site-specific complement regulation,
with Crry principally on the soles and DAF on the apicaldifference in C3 staining intensity by IF microscopy.
Since differences in C3 staining intensity do not always surfaces, corresponding to their locations in vivo.
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It is important to point out the limitations of our stud- tent of glomerulosclerosis and C3 deposition. Notably,
in contrast to the prominent tubular deposition of C3,ies examining the role of DAF in vivo. For these, Abs
were injected that inhibited the function of DAF in vitro; glomerular C3 staining was relatively modest at all times
in the disease course. Based upon our data, it does seemsuch an experimental strategy is commonly used [31, 67].
In practical terms, this was the only approach available likely that DAF on GEC does hasten the recovery from
the renal failure that occurs in this model, and thus com-as we lacked an inhibitory pharmacologic agent or rats
that were genetically deficient in DAF. One important plement activation on these cells is of pathogenic signifi-
cance in PAN nephrosis.issue is how much of the injected anti-DAF F(ab)2 Abs
actually bound to their designated target on the GEC. Rat glomerular DAF is predicted to be anchored to
the GEC plasma membrane through a GPI linkage [25].With the use of large quantities of injected Abs (up to
40 mg), significant binding to glomeruli was apparent soon Similarly, CD59 has a GPI anchor [69]. The GEC has
an interesting polarization with the apical surface freeafter injection. With this, immunoreactive DAF declined,
either due to antigenic modulation and/or to epitope in the urinary space, while the basal surface is opposed
masking by the bound anti-DAF Abs. However, the fact to the glomerular basement membrane. Such a polariza-
that DAF has a widespread distribution in the rat includ- tion of GPI-linked proteins to apical surfaces has been
ing on endothelia and blood cells [29] means that the reported for many epithelial cells and, therefore, GEC
injected Abs had many targets, and it is likely only a appear to follow this general rule applicable to epithelial
minority of that injected was available for glomerular cells [70, 71].
binding. Furthermore, the 90 kD F(ab)2 molecule In summary, our study characterizes DAF present on
would have limited access across the glomerular base- rat GEC. In GEC in vitro, DAF is an effective comple-
ment membrane and GEC slit diaphragm to access the ment regulator, and works in concert with CD59 to limit
apical surface of GEC. Given these considerations, it is complement activation. In GEC in vivo, DAF is present
likely that DAF was not inhibited in its entirety in these extensively and exclusively on the apical surfaces of GEC.
studies, and we must be cautious in our interpretations Yet, it may not be essential to prevent complement acti-
that DAF does not play any role in complement regula- vation from occurring under normal circumstances and
tion in vivo. in those cases in which complement-activating Abs are
Under physiological circumstances, or even those in present on the basal surfaces of GEC in vivo. However,
which anti-megalin Abs are present, there is relatively in proteinuric conditions, DAF appears to protect GEC
little protein accessibility to the GEC. In our studies, from spontaneous complement activation from the fil-
such relevant proteins include both the activating com- tered complement proteins. Whether DAF also has a role
plement proteins and the neutralizing anti-DAF Abs. completely removed from its complement regulatory ac-
Therefore, the PAN nephrosis model was used as a tivity, such as transducing signals to GEC [56], remains
model in which there is marked protein passage across to be determined.
the glomerular capillary wall. At the time of injection
of anti-DAF (or pre-immune control) Abs, animals had ACKNOWLEDGMENTS
heavy proteinuria and renal insufficiency, the latter at-
This work was supported by National Institutes of Health grants
tributable, at least in part, to complement activation on DK34972 (DRA) and DK41873 (RJQ), and by the Wellcome Trust
Senior Clinical Fellowship (BPM). Drs. Bao, Cunningham and Do-the tubules [39, 68]. Neutralization of DAF function had
shi were supported by National Institutes of Health Training Grantno effect on proteinuria, glomerular or tubular comple-
DK07510. We thank Dr. Donna Mendrick for supplying the anti-ment deposition or histological features of disease. How- megalin Abs and Randy Anderson for expert technical assistance.
ever, animals in which DAF function was neutralized
Reprint requests to L. Bao, M.D., Ph.D., The University of Chicago,did not recover normal renal function by day 11 of the
Section of Nephrology, 5841 S. Maryland Ave., MC5100, Chicago, Illi-model compared to those animals receiving pre-immune nois 60637, USA.
IgG. The renal failure in this model is interesting, and E-mail: lbao@medicine.uchicago.edu.
may well be attributable to complement activation on
the renal tubules [39, 68]. Consistent with this was the REFERENCES
presence of a marked degree of complement activation
1. Liszewski MK, Atkinson JP: The complement system (chapt 26),
on tubules and a modest degree of histological damage. in Fundamental Immunology (3rd ed), edited by Paul WE, New
York, Raven Press, 1993, pp 917–939Not surprisingly, neutralization of DAF function af-
2. Walport MJ: Advances in immunology: Complement (first of twofected neither of these, as our current study showed DAF
parts). N Engl J Med 344:1058–1066, 2001
to be absent from tubular cells, while the complement 3. Nicholson-Weller A, Halperin JA: Membrane signaling by com-
plement C5b-9, the membrane attack complex. Immunol Res 12:regulator Crry has a protective role in this model [68].
244–257, 1993It is interesting that while anti-DAF clearly altered glo-
4. Liszewski MK, Farries TC, Lublin DM, et al: Control of the
merular filtration, it did not affect histological measures complement system. Adv Immunol 61:201–283, 1996
5. Campbell RD, Law SKA, Reid KBM, et al: Structure, organiza-of glomerular disease in this model, those being the ex-
Bao et al: Rat glomerular epithelial cell DAF2020
tion, and regulation of the complement genes. Ann Rev Immunol bited by the nephritogenic antibody of passive Heymann nephritis.
J Immunol 154:3437–3443, 19956:161–195, 1988
28. Schiller B, He C, Salant DJ, et al: Inhibition of complement6. Foley S, Li B, Dehoff M, et al: Mouse Crry/p65 is a regulator of
regulation is key to the pathogenesis of Heymann nephritis. J Expthe alternative pathway of complement activation. Eur J Immunol
Med 188:1353–1358, 199823:1381–1384, 1993
29. Spiller OB, Hanna SM, Morgan BP: Tissue distribution of the7. Kim Y-U, Kinoshita T, Molina H, et al: Mouse complement regu-
rat analogue of decay accelerating factor. Immunology 97:374–latory protein Crry/p65 uses the specific mechanisms of both human
384, 1999decay-accelerating factor and membrane cofactor protein. J Exp
30. Hinchliffe SJ, Spiller OB, Rushmere NK, et al: Molecular cloningMed 181:151–159, 1995
and functional characterization of the rat analogue of human de-8. Couser WG: Pathogenesis of glomerular damage in glomerulo-
cay-accelerating factor. J Immunol 161:5695–5703, 1998nephritis. Nephrol Dial Transplant 13(Suppl 1):10–15, 1998
31. Cunningham PN, Hack BK, Ren G, et al: Glomerular complement9. Cybulsky AV, Foster MH, Salant DJ, Quigg RJ: Immunologic
regulation is overwhelmed in passive Heymann nephritis. Kidneymechanisms of glomerular disease, in The Kidney: Physiology and
Int 60:900–909, 2001Pathophysiology (3rd ed), edited by Seldin DW, Giebisch G,
32. Mendrick DL, Chung DC, Rennke HG: Heymann antigen GP330Philadelphia, Lippincott-Raven, 2000, pp 2645–2697
demonstrates affinity for fibronectin, laminin, and type I collagen10. Kerjaschki D, Neale TJ: Molecular mechanisms of glomerular
and mediates rat proximal tubule epithelial cell adherence to suchinjury in rat experimental membranous nephropathy (Heymann
matrices in vitro. Exp Cell Res 188:23–35, 1990nephritis). J Am Soc Nephrol 7:2518–2526, 1996
33. Hughes TR, Piddlesden SJ, Williams JD, et al: Isolation and11. Kerjaschki D, Miettinen A, Farquhar MG: Initial events in the
characterization of a membrane protein from rat erythrocytesformation of immune deposits in passive Heymann nephritis.
which inhibits lysis by the membrane attack complex of rat comple-gp330-anti-gp330 immune complexes form in epithelial coated pits
ment. Biochem J 284:169–176, 1992and rapidly become attached to the glomerular basement mem-
34. Holt DS, Botto M, Bygrave AE, et al: Targeted deletion ofbrane. J Exp Med 166:109–128, 1987
the CD59 gene causes spontaneous intravascular hemolysis and12. Makker SP, Singh AK: Characterization of the antigen (gp600)
hemoglobinuria. Blood 98:442–449, 2001of Heymann nephritis. Lab Invest 50:287–293, 1984
35. Quigg RJ, Cybulsky AV, Salant DJ: Effect of nephritogenic13. Quigg RJ, Abrahamson DR, Cybulsky AV, et al: Studies with
antibody on complement regulation in cultured rat glomerularantibodies to cultured rat glomerular epithelial cells: Subepithe-
epithelial cells. J Immunol 147:838–845, 1991lial immune deposit formation after in vivo injection. Am J Pathol
36. Salant DJ, Madaio MP, Adler S, et al: Altered glomerular perme-134:1125–1133, 1989
ability induced by F(ab’)2 and Fab’ antibodies to rat renal tubular14. Salant DJ, Quigg RJ, Cybulsky AV: Heymann nephritis: Mecha-
epithelial antigen. Kidney Int 21:36–43, 1982nisms of renal injury. Kidney Int 35:976–984, 1989
37. Levidiotis V, Kanellis J, Ierino FL, et al: Increased expression15. Cybulsky AV, Quigg RJ, Salant DJ: Role of the complement
of heparanase in puromycin aminonucleoside nephrosis. Kidneymembrane attack complex in glomerular injury, (chapt 3), in Con-
Int 60:1287–1296, 2001temporary Issues in Nephrology. Immunopathology of Renal Dis- 38. Quigg RJ, Lim A, Haas M, et al: Immune complex glomerulo-ease (18th ed), edited by Wilson CB, Brenner BM, Stein JH, nephritis in C4- and C3-deficient mice. Kidney Int 53:320–330, 1998
New York, Churchill Livingstone, 1988, pp 57–86 39. Nomura A, Morita Y, Maruyama S, et al: Role of complement
16. Salant DJ, Belok S, Madaio MP, et al: A new role for complement in acute tubulointerstitial injury of rats with aminonucleoside ne-
in experimental membranous nephropathy in rats. J Clin Invest phrosis. Am J Pathol 151:539–547, 1997
66:1339–1350, 1980 40. Schulze M, Pruchno CJ, Burns M, et al: Glomerular C3c local-
17. Salant DJ, Darby C, Couser WG: Experimental membranous ization indicates ongoing immune deposit formation and comple-
glomerulonephritis in rats. Quantitative studies of glomerular im- ment activation in experimental glomerulonephritis. Am J Pathol
mune deposit formation in isolated glomeruli and whole animals. 142:179–187, 1993
J Clin Invest 66:71–81, 1980 41. Nicholson-Weller A, March JP, Rosenfeld SI, et al: Affected
18. Somlo S, Mundel P: Getting a foothold in nephrotic syndrome. erythrocytes of patients with paroxysmal nocturnal hemoglobin-
Nat Genet 24:333–335, 2000 uria are deficient in the complement regulatory protein, decay
19. Ryan GB, Karnovsky MJ: An ultrastructural study of the mecha- accelerating factor. Proc Natl Acad Sci USA 80:5066–5070, 1983
nisms of proteinuria in aminonucleoside nephrosis. Kidney Int 42. Sun X, Funk CD, Deng C, et al: Role of decay-accelerating fac-
8:219–232, 1975 tor in regulating complement activation on the erythrocyte sur-
20. Fishman JA, Karnovsky MJ: Effects of the aminonucleoside of face as revealed by gene targeting. Proc Natl Acad Sci USA 96:628–
puromycin on glomerular epithelial cells in vitro. Am J Pathol 118: 633, 1999
398–407, 1985 43. Nicholson-Weller A, Burge J, Fearon DT, et al: Isolation of a
21. Nangaku M: Complement regulatory proteins in glomerular dis- human erythrocyte membrane glycoprotein with decay-accelerat-
eases. Kidney Int 54:1419–1428, 1998 ing activity for C3 convertases of the complement system. J Immu-
22. Rushmere NK, Van Den Berg CW, Harrison RA, et al: Molecular nol 129:184–189, 1982
cloning of the rat analogue of human CD59: structural comparison 44. Nicholson-Weller A, Burge J, Austen KF: Purification from
with human CD59 and identification of a putative active site. Bio- guinea pig erythrocyte stroma of a decay-accelerating factor for the
chem J 304:595–601, 1994 classical C3 convertase, C4b,2a. J Immunol 127:2035–2039, 1981
23. Ichida S, Yuzawa Y, Okada H, et al: Localization of the comple- 45. Rey-Campos J, Rubinstein P, Rodriguez De Cordoba S: A physi-
ment regulatory proteins in the normal human kidney. Kidney Int cal map of the human regulator of complement activation gene
46:89–96, 1994 cluster linking the complement genes CR1, CR2, DAF, and C4BP.
24. Nakanishi I, Moutabarrik A, Hara T, et al: Identification and J Exp Med 167:664–669, 1988
characterization of membrane cofactor protein (CD46) in the hu- 46. Hourcade D, Holers VM, Atkinson JP: The regulators of
man kidneys. Eur J Immunol 24:1529–1535, 1994 complement activation (RCA) gene cluster. Adv Immunol 45:381–
25. Quigg RJ, Nicholson-Weller A, Cybulsky AV, et al: Decay 416, 1989
accelerating factor regulates complement activation on glomerular 47. Kingsmore SF, Vik DP, Kurtz CB, et al: Genetic organization
epithelial cells. J Immunol 142:877–882, 1989 of complement receptor-related genes in the mouse. J Exp Med
26. Quigg RJ, Morgan BP, Holers VM, et al: Complement regula- 169:1479–1484, 1989
tion in the rat glomerulus: Crry and CD59 regulate complement 48. Spicer AP, Seldin MF, Gendler SJ: Molecular cloning and chro-
in glomerular mesangial and endothelial cells. Kidney Int 48:412– mosomal localization of the mouse decay-accelerating factor genes.
421, 1995 J Immunol 155:3079–3091, 1995
27. Quigg RJ, Holers VM, Morgan BP, et al: Crry and CD59 regu- 49. Kurtz CB, O’Toole E, Christensen SM, et al: The murine comple-
ment receptor gene family. IV. Alternative splicing of Cr2 genelate complement in rat glomerular epithelial cells and are inhi-
Bao et al: Rat glomerular epithelial cell DAF 2021
transcripts predicts two distinct gene products that share homolo- regulatory proteins in diffuse proliferative glomerulonephritis. Lu-
pus 9:127–131, 2000gous domains with both human CR2 and CR1. J Immunol 144:
61. Abe K, Miyazaki M, Koji T, et al: Expression of decay accelerating3581–3591, 1990
factor mRNA and complement C3 mRNA in human diseased50. Molina H, Kinoshita T, Inoue K, et al: A molecular and immuno-
kidney. Kidney Int 54:120–130, 1998chemical characterization of mouse CR2. Evidence for a single
62. Shibata T, Cosio FG, Birmingham DJ: Complement activationgene model of mouse complement receptors 1 and 2. J Immunol
induces the expression of decay-accelerating factor on human mes-145:2974–2983, 1990
angial cells. J Immunol 147:3901–3908, 199151. Paul MS, Aegerter M, O’Brien SE, et al: The murine complement
63. Lin F, Fukuoka Y, Spicer A, et al: Tissue distribution of productsreceptor gene family. I. Analysis of mCRY gene products and
of the mouse decay-accelerating factor (DAF) genes. Exploitationtheir homology to human CR1. J Immunol 142:582–589, 1989
of a Daf1 knock-out mouse and site-specific monoclonal antibodies.52. Takizawa H, Okada N, Okada H: Complement inhibitor of rat
Immunology 104:215–225, 2001cell membrane resembling mouse Crry/p65. J Immunol 152:3032–
64. Sogabe H, Nangaku M, Ishibashi Y, et al: Increased susceptibil-3038, 1994
ity of decay-accelerating factor deficient mice to anti-glomerular53. Song WC, Deng C, Raszmann K, et al: Mouse decay-accelerating
basement membrane glomerulonephritis. J Immunol 167:2791–factor: selective and tissue-specific induction by estrogen of the
2797, 2001gene encoding the glycosylphosphatidylinositol-anchored form.
65. Lin F, Emancipator SN, Salant DJ, et al: Decay-acceleratingJ Immunol 157:4166–4172, 1996
factor confers protection against complement-mediated podocyte54. Mead R, Hinchliffe SJ, Morgan BP: Molecular cloning, expres-
injury in acute nephrotoxic nephritis. Lab Invest 82:563–569, 2002sion and characterization of the rat analogue of human membrane
66. Camussi G, Brentjens JR, Noble B, et al: Antibody-induced redis-cofactor protein (MCP/CD46). Immunology 98:137–143, 1999
tribution of Heymann antigen on the surface of cultured glomerular55. Miwa T, Nonaka M, Okada N, et al: Molecular cloning of rat
visceral epithelial cells: Possible role in the pathogenesis of Hey-and mouse membrane cofactor protein (MCP, CD46): Preferential mann glomerulonephritis. J Immunol 135:2409–2416, 1985expression in testis and close linkage between the mouse Mcp and 67. Matsuo S, Ichida S, Takizawa H, et al: In vivo effects of mono-Cr2 genes on distal chromosome 1. Immunogenetics 48:363–371, 1998 clonal autibodies that functionally inhibit complement regulatory
56. Nicholson-Weller A, Wang C: Structure and function of decay proteins in rats. J Exp Med 180:1619–1627, 1994
accelerating factor CD55. J Lab Clin Med 123:485–491, 1994 68. Hori Y, Yamada K, Hanafusa N, et al: Crry, a complement regula-
57. Walter EI, Ratnoff WD, Long KE, et al: Effect of glycoinosi- tory protein, modulates renal interstitial disease induced by pro-
tolphospholipid anchor lipid groups on functional properties of teinuria. Kidney Int 56:2096–2106, 1999
decay-accelerating factor protein in cells. J Biol Chem 267:1245– 69. Ratnoff WD, Knez JJ, Prince GM, et al: Structural properties of
1252, 1992 the glycoplasmanylinositol anchor phospholipid of the complement
58. Medof ME, Walter EI, Rutgers JL, et al: Identification of the membrane attack complex inhibitor CD59. Clin Exp Immunol 87:
complement decay-accelerating factor (DAF) on epithelium and 415–421, 1992
glandular cells and in body fluids. J Exp Med 165:848–864, 1987 70. Brown DA, Crise B, Rose JK: Mechanism of membrane anchoring
59. Cosio FG, Sedmak DD, Mahan JD, et al: Localization of decay affects polarized expression of two proteins in MDCK cells. Science
accelerating factor in normal and diseased kidneys. Kidney Int 36: 245:1499–1501, 1989
100–107, 1989 71. Le Gall AH, Yeaman C, Muesch A, et al: Epithelial cell polarity:
New perspectives. Semin Nephrol 15:272–284, 199560. Arora M, Arora R, Tiwari SC, et al: Expression of complement
